Epidiolex

The stocks of pharmaceutical companies often trade in sympathy with one another. It’s common for companies working on similar and/or competing drugs to trade in tandem or inversely when one company gets major news about one of its drug candidates. For example, if a drug candidate gets...

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH), a developer of cannabinoid prescription medicines, saw its stock surge Monday after the company reported positive results from a clinical study. Wall Street took notice with some firms reaffirming their bullish stance on the stock and placing price...

GW Pharmaceuticals PLC (NASDAQ: GWPH)'s stock gained more than 17 percent Monday following the company's announcement of a second successful pivotal trial in an ongoing Phase 3 trial exploring its lead cannabinoid product, Epidiolex. GW Pharma's strong gains helped boost shares of...

Shares of GW Pharmaceuticals PLC (NASDAQ: GWPH) were trading higher by more than 17 percent Monday, but analysts at Cantor Fitzgerald believe the surge has just begun. GW Pharma announced a second successful pivotal trial in an ongoing Phase 3 trial which explores Epidiolex, its lead...

Shares of GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH), a developer of cannabinoid prescription medicines, spiked by more than 10 percent Monday morning following the company's announcement that Epidiolex achieved a primary endpoint in a Phase 3 clinical study. Epidiolex, GW Pharma's lead...

GW Pharmaceuticals plc (NASDAQ: GWPH) revealed Epidiolex has achieved primary endpoint in treating Lennox-Gastaut syndrome. The positive results came from its randomized, double-blind and placebo-controlled final stage clinical study. Earlier in June, the company disclosed favorable results...

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) has dipped below $85 for the first time since June and is now on the brink of a technical breakdown. After a huge jump back in March following positive Phase 3 data on Epidiolex, the stock has traded in the bullish channel included on the chart below...

GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH) has risen to $91.57 since its previous Vetr rating of 2.5 stars was issued two days ago. On Friday, the Vetr community upgraded their rating to three stars. The British pharmaceutical company rallied on Tuesday on the release of positive data from their...

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH)'s Epidiolex met primary endpoint in the phase three pivotal trial results for the treatment of Lennox-Gastaut Syndrome. The primary endpoint was achieved with superior statistical significance demonstrating that Epidiolex treatment reduces drop...

Cantor Fitzgerald's Elemer Piros is positive on GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH)'s technology value of its drug portfolio and estimated year-end 2016 cash position. He has a bullish view on the potential for Epidiolex following the published anecdotal evidence on the impact to...

Shares of GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH) are up nearly 120 percent in early Monday trading after the company announced positive Phase III data on Epidiolex. The study found that the drug significantly reduced seizures in children suffering from Dravet Syndrome, a condition for which...

Healthcare has been one of the best performing sectors of the U.S. stock market for years, but in 2015, shares of healthcare stocks have suffered slightly. Many investors began to worry about the impact next year's presidential election might have on the sector. Some candidates have voiced concern...

GW Pharmaceuticals (NASDAQ: GWPH) is planning to issue 1.25 million American Depositary shares in a public offering in an effort to raise some fresh cash. The company hasn't provided many details about the offering, but investors are speculating that the firm is looking to continue...